期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
3.0 T磁共振动态增强及扩散加权成像在浸润性乳腺癌腋窝淋巴结转移诊断中的应用价值 被引量:23
1
作者 罗兆丽 杨春华 +2 位作者 王芳芳 姚辉莉 刘跃娜 《实用医院临床杂志》 2022年第4期173-177,共5页
目的探讨应用3.0 T磁共振动态增强(MRI-DCE)及扩散加权成像(DWI)诊断浸润性乳腺癌腋窝淋巴结(ALN)转移的价值。方法我院收治的143例早期浸润性乳腺癌患者,均接受MRI-DCE及DWI评估ALN转移情况,分析两者在ALN转移中诊断价值。结果以病理... 目的探讨应用3.0 T磁共振动态增强(MRI-DCE)及扩散加权成像(DWI)诊断浸润性乳腺癌腋窝淋巴结(ALN)转移的价值。方法我院收治的143例早期浸润性乳腺癌患者,均接受MRI-DCE及DWI评估ALN转移情况,分析两者在ALN转移中诊断价值。结果以病理诊断为金标准,MRI-DCE联合DWI诊断ALN灵敏度、特异度、阳性预测值与阴性预测值分别为94.59%、96.23%、89.74%与98.08%;ALN转移与无ALN转移患者边界、早期强化模式、DWI信号、长径、短径、早期强化率、最大强化率、皮质厚度、表观扩散系数(ADC)值等MRI表现比较,差异有统计学意义(P<0.05);DWI高信号、短径及ADC值是ALN转移的影响因素(P<0.05);DWI信号、短径及ADC值诊断ALN转移曲线下面积(AUC)为0.619、0.745、0.734,各指标联合诊断ALN转移AUC值为0.835。结论3.0 T MR动态增强及扩散加权成像可以有效检出早期浸润性乳腺癌ALN转移,测定DWI信号、短径及ADC值联合有助于提高患者ALN转移诊断价值。 展开更多
关键词 3.0 t磁共振 动态增强扫描 扩散加权成像 浸润性乳腺癌 腋窝淋巴结转移 诊断价值
下载PDF
3.0 T磁共振弥散加权成像及动态增强扫描对乳腺癌的诊断价值 被引量:4
2
作者 周志强 秦思思 +2 位作者 张昕昕 张秀玲 殷倩 《医学研究与教育》 CAS 2021年第5期7-14,共8页
目的探讨3.0 T磁共振弥散加权成像及动态增强扫描对于乳腺癌的应用价值。方法选取保定市第二医院2016年12月至2019年12月,使用Siemens 3.0 T磁共振检出的总共188例患有210个乳腺肿瘤(136个恶性和74个良性)的患者,根据乳腺影像报告和数... 目的探讨3.0 T磁共振弥散加权成像及动态增强扫描对于乳腺癌的应用价值。方法选取保定市第二医院2016年12月至2019年12月,使用Siemens 3.0 T磁共振检出的总共188例患有210个乳腺肿瘤(136个恶性和74个良性)的患者,根据乳腺影像报告和数据系统(breast imaging reporting and data system,BI-RADS)分级以及弥散加权成像(diffusion weighted imaging,DWI)描述指标,在磁共振动态增强(dynamic contrast-enhanced,DCE)扫描和T2加权成像上标记肿块(n=182)和非肿块(n=28),同时使用BI-RADS描述指标中DCE、T2加权成像和表观扩散(弥散)系数(apparent diffusion coefficient,ADC)的特点,以ADC≤1.255×10-3 mm2/s作为标准区分良性和恶性病变的标准,与手术或穿刺活检病理结果进行对照,采用统计学方法分析得出结果。结果在模型1中,ADCmean(P<0.003)、DCE肿块边缘(P=0.002)和DCE平台型或流出型增强(P=0.001)与乳腺癌的诊断显著且独立相关。模型2确定ADCmean(P=0.001)、DCE肿块边缘(P=0.001)、早期快速强化(P=0.042)和DCE平台型或流出型增强(P=0.001)与乳腺癌诊断显著独立相关。T2加权成像变量未包含在最终模型中。结论使用3.0 T磁共振采用多通道乳腺专用线圈检查,其DCE和DWI定量和定性描述指标的模型可实现准确的乳腺癌诊断,联合应用可以显著提高乳腺癌的诊断准确率。且发现T2加权成像对乳腺癌的诊断没有显著贡献。 展开更多
关键词 乳腺癌 动态增强扫描 弥散加权成像 t_(2)加权成像 3.0 t磁共振 乳腺影像报告和数据系统
下载PDF
Preclinical Long-term Magnetic Resonance Imaging Study of Silymarin Liver-protective Effects
3
作者 Yeon Ji Chae Hwon Heo +8 位作者 Chul-Woong Woo Sang-Tae Kim Jae-Im Kwon Monica Young Choi Yu Sub Sung Kyung Won Kim Jeong Kon Kim Yoonseok Choi Dong-Cheol Woo 《Journal of Clinical and Translational Hepatology》 SCIE 2022年第6期1167-1175,共9页
Background and Aims:Efficacy evaluations with preclini-cal magnetic resonance imaging(MRI)are uncommon,but MRI in the preclinical phase of drug development provides information that is useful for longitudinal monitori... Background and Aims:Efficacy evaluations with preclini-cal magnetic resonance imaging(MRI)are uncommon,but MRI in the preclinical phase of drug development provides information that is useful for longitudinal monitoring.The study aim was to monitor the protective effectiveness of silymarin with multiparameter MRI and biomarkers in a thioacetamide(TAA)-induced model of liver injury in rats.Correlation analysis was conducted to assess compare the monitoring of liver function by MRI and biomarkers.Meth-ods:TAA was injected three times a week for 8 weeks to generate a disease model(TAA group).In the TAA and sily-marin-treated(TAA-SY)groups,silymarin was administered three times weekly from week 4.MR images were acquired at 0,2,4,6,and 8 weeks in the control,TAA,and TAA-SY groups.Results:The area under the curve to maximum time(AUCtmax)and T_(2)*values of the TAA group decreased over the study period,but the serological markers of liver abnormality increased significantly more than those in the control group.In the TAA-SY group,MRI and serological biomarkers indicated attenuation of liver function as in the TAA group.However,pattern changes were observed from week 6 to comparable levels in the control group with si-lymarin treatment.Negative correlations between either AUCtmax or T_(2)*values and the serological biomarkers were observed.Conclusions:Silymarin had hepatoprotective effects on TAA-induced liver injury and demonstrated the usefulness of multiparametric MRI to evaluate efficacy in preclinical studies of liver drug development. 展开更多
关键词 Liver fibrosis Magnetic resonance imaging SILYMARIN t1-weight-ed dynamic contrast-enhanced t_(2)*
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部